High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer

Eur J Cancer Clin Oncol. 1987 Sep;23(9):1303-6. doi: 10.1016/0277-5379(87)90112-x.

Abstract

The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50% survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / mortality
  • Diarrhea / chemically induced
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Humans
  • Leucovorin / administration & dosage
  • Leucovorin / adverse effects
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Mouth Mucosa
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / mortality
  • Stomatitis / chemically induced

Substances

  • Leucovorin
  • Fluorouracil